

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	0	(2002/0172967).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L2	0	(2002/00172967).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L3	2	("20020172967").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L4	2	("5700811").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L5	2	("5369108").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L6	2	("6087367").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L7	135	(562/622).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L8	510	(514/575).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/27 11:36
L9	38	L7 and L8	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/12/27 11:36
L10	19358	benzamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/12/27 11:36
L11	607	L7 or L8	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/12/27 11:36

## EAST Search History

L12	102	L10 and L11	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/12/27 11:36
-----	-----	-------------	---	----	----	------------------

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	28	DEC 18	CA/CAplus patent kind codes updated
NEWS	29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	30	DEC 18	MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8      For general information regarding STN implementation of IPC 8  
NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:53:00 ON 27 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:53:16 ON 27 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

DICTIONARY FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10595124\10595124 clm 1 genus complete.str



```

chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 27 29 31 48 49 54
ring nodes :
1 2 3 4 5 6 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47
chain bonds :
2-31 5-7 7-8 8-9 8-11 9-10 9-12 13-14 13-27 14-17 15-16 15-18 16-29
31-54 43-49 44-48
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 32-33 32-37 32-40 33-34 34-35 34-38 35-36
36-37 36-41 38-39 39-40 39-41 42-43 42-47 43-44 44-45 45-46 46-47
exact/norm bonds :
2-31 8-9 8-11 9-10 13-14 13-27 14-17 15-16 15-18 16-29 31-54 32-33
32-37 32-40 33-34 34-35 34-38 35-36 36-37 36-41 38-39 39-40 39-41 43-49
44-48
exact bonds :
5-7 7-8 9-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 42-43 42-47 43-44 44-45 45-46 46-47

```

G1:H, [\*1]

G2:[\*2-\*3], [\*4-\*5]

G3:[\*6], [\*7]

Hydrogen count :

42:>= minimum 1 45:>= minimum 1 47:>= minimum 1

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS  
 19:CLASS 27:CLASS 29:CLASS 31:CLASS 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom  
 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom  
 46:Atom 47:Atom 48:CLASS 49:CLASS 54:CLASS

Element Count :

Node 19: Limited

C, Cl-2

L1           STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1           STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> d l1

L1 HAS NO ANSWERS

L1           STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 07:54:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 902 TO ITERATE

100.0% PROCESSED           902 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*  
                          BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:           16239 TO   19841

PROJECTED ANSWERS:               1 TO       80


L2           1 SEA SSS SAM L1

=> d scan

L2   1 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN

IN   Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-3,4-dimethyl- (9CI)

MF   C16 H16 N2 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST ENTRY SESSION  
0.88 1.09

FILE 'CAPLUS' ENTERED AT 07:54:30 ON 27 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Dec 2006 VOL 146 ISS 1  
FILE LAST UPDATED: 26 Dec 2006 (20061226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 12

L3 1 L2

=> d 13 ti fbib abs


L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.  
AN 2005:182616 CAPLUS  
DN 142:279954  
TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.  
IN Rho, Ho Sik; Baek, Heung Soo; Kim, Su Jong; Kim, Su Nam; Chae, Byung Geun; Lee, Byoung Seok; Kim, Bae Hwan; Choi, Gyu Ho; Son, Eui Dong; Lee, Hae Kwang; Lee, Hye Won; Cho, Jun-cheol; Kim, Duck Hee; Chang, Ih Seop; Lee, Ok Sub  
PA Amorepacific Corporation, S. Korea  
SO PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019162	A1	20050303	WO 2004-KR2143	20040826
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

KR 2006005892	A	20060118	KR 2003-59177	A	20030826
EP 1660437	A1	20060531	KR 2004-20401	A	20040325
R: FR			KR 2004-54886	A	20040714
			KR 2004-54886		20040714
			EP 2004-774404		20040826

			KR 2003-59177	A	20030826
			KR 2004-20401	A	20040325
			KR 2004-54886	A	20040714
CN 1839115	A	20060927	WO 2004-KR2143	W	20040826
			CN 2004-80024139		20040826
			KR 2003-59177	A	20030826
			KR 2004-20401	A	20040325
			KR 2004-54886	A	20040714
US 2006252834	A1	20061109	WO 2004-KR2143	W	20040826
			US 2006-595124		20060615
			KR 2003-59177	A	20030826
			KR 2004-20401	A	20040325
			KR 2004-54886	A	20040714
			WO 2004-KR2143	W	20040826

OS MARPAT 142:279954  
GI



AB Title compds. [I; R1 = adamantyl, Q1; R5, R6 = H, alkyl, cycloalkyl; R2 = CONH, NHCO, CONR7, NR7CO; R7 = alkyl; R3 = (CH)<sub>n</sub>; n = 0, 1; R4 = H, alkyl], were prepared Thus, 4-(phenylcarbonylamino)benzoic acid (preparation given) in pyridine at 10° was treated dropwise with Et chloroformate followed by stirring for 2 h at room temperature to give the anhydride. This was added to NH<sub>2</sub>OH.HCl in pyridine at 10° followed by stirring for 30 min. to give 65% N-[4-(N-hydroxycarbamoyl)phenyl]benzamide. The latter reduced collagenase expression in vitro to 78% of controls, vs. 85% for retinol.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.20

4.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.75

-0.75

FILE 'REGISTRY' ENTERED AT 07:55:14 ON 27 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.



STRUCTURE FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6  
DICTIONARY FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his

(FILE 'HOME' ENTERED AT 07:53:00 ON 27 DEC 2006)

FILE 'REGISTRY' ENTERED AT 07:53:16 ON 27 DEC 2006

L1 STRUCTURE UPLOADED

L2 1 SEARCH L1 SSS SAM

FILE 'CAPLUS' ENTERED AT 07:54:30 ON 27 DEC 2006

L3 1 L2

FILE 'REGISTRY' ENTERED AT 07:55:14 ON 27 DEC 2006

=> search l1 sss full

FULL SEARCH INITIATED 07:56:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 18609 TO ITERATE

100.0% PROCESSED 18609 ITERATIONS

35 ANSWERS

SEARCH TIME: 00.00.01


L4 35 SEA SSS FUL L1

=> d scan

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1,4-Benzenedicarboxamide, N'-hydroxy-N-methyl-N-(4-methylphenyl)- (9CI)

MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):35

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


IN Benzeneacetamide, 4-(benzoylamino)-N-hydroxy- (9CI)

MF C15 H14 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, 4-(benzoylamino)-N-hydroxy- (9CI)  
 MF C14 H12 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1,4-Benzenedicarboxamide, N-(4-ethylphenyl)-N'-hydroxy-N-methyl- (9CI)  
 MF C17 H18 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzeneacetamide, 4-[(4-ethylbenzoyl)amino]-N-hydroxy- (9CI)  
 MF C17 H18 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(4-ethylbenzoyl)amino]-N-hydroxy- (9CI)  
MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1,4-Benzenedicarboxamide, N'-hydroxy-N-methyl-N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl- (9CI)  
MF C19 H24 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Tricyclo[3.3.1.1<sup>3,7</sup>]decane-1-carboxamide, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]- (9CI)  
MF C19 H24 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Tricyclo[3.3.1.1<sup>3,7</sup>]decane-1-carboxamide, N-[4-  
[(hydroxyamino)carbonyl]phenyl]- (9CI)  
MF C18 H22 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, 4-[(4-cyanobenzoyl)amino]-N-hydroxy- (9CI)  
 MF C15 H11 N3 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-(3-methylphenyl)- (9CI)  
 MF C15 H14 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-N,4-dimethyl- (9CI)  
 MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benamide, 4-cyano-N-[4-[(hydroxyamino)carbonyl]phenyl]-N-methyl- (9CI)  
MF C16 H13 N3 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1,4-Benzenedicarboxamide, N-(3,4-dimethylphenyl)-N'-hydroxy- (9CI)  
MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benamide, 4-ethyl-N-[4-[(hydroxyamino)carbonyl]phenyl]-N-methyl- (9CI)  
MF C17 H18 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-phenyl- (9CI)  
MF C14 H12 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1,4-Benzenedicarboxamide, N'-hydroxy-N-methyl-N-phenyl- (9CI)  
 MF C15 H14 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Tricyclo[3.3.1.1<sup>3,7</sup>]decane-1-carboxamide, N-[4-  
 [(hydroxyamino)carbonyl]phenyl]-N-methyl- (9CI)  
 MF C19 H24 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzeneacetamide, N-hydroxy-4-[(4-methylbenzoyl)amino]- (9CI)  
 MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1,4-Benzenedicarboxamide, N'-hydroxy-N-methyl-N-(3-methylphenyl)- (9CI)  
 MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzeneacetamide, N-hydroxy-4-[(3-methylbenzoyl)amino]- (9CI)  
 MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-3-methyl- (9CI)  
 MF C15 H14 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1,4-Benzenedicarboxamide, N-(3,4-dimethylphenyl)-N'-hydroxy-N-methyl- (9CI)  
MF C17 H18 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzeneacetamide, 4-[(3,4-dimethylbenzoyl)amino]-N-hydroxy- (9CI)  
MF C17 H18 N2 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-3,4-dimethyl- (9CI)  
MF C16 H16 N2 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-4-(trifluoromethyl)- (9CI)  
MF C15 H11 F3 N2 O3






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-(4-methylphenyl)- (9CI)  
 MF C15 H14 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benamide, 4-(benzoylmethylamino)-N-hydroxy- (9CI)  
 MF C15 H14 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzoic acid, 4-[[[4-[(hydroxyamino)carbonyl]phenyl]amino]carbonyl]- (9CI)  
 MF C15 H12 N2 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1,4-Benzenedicarboxamide, N-(4-ethylphenyl)-N'-hydroxy- (9CI)  
MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-N,3-dimethyl- (9CI)  
MF C16 H16 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzoic acid, 4-[[[4-[(hydroxyamino)carbonyl]phenyl]methylamino]carbonyl]- (9CI)  
MF C16 H14 N2 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl- (9CI)  
MF C18 H22 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-N,3,4-trimethyl- (9CI)  
 MF C17 H18 N2 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L4 35 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-4-methyl- (9CI)  
 MF C15 H14 N2 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

168.26

SINCE FILE

ENTRY

0.00

TOTAL

SESSION

172.55

TOTAL

SESSION

-0.75

FILE 'REGISTRY' ENTERED AT 07:57:50 ON 27 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6  
DICTIONARY FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.44	172.99

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.75

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 07:57:59 ON 27 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 27 Dec 2006 VOL 146 ISS 1  
FILE LAST UPDATED: 26 Dec 2006 (20061226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 14

L5 9 L4

=> d 15 1-9 ti fbib abs

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Hydroxamic acid derivative histone deacetylase inhibitors, and their

therapeutic use  
 AN 2006:333299 CAPLUS  
 DN 144:343645  
 TI Hydroxamic acid derivative histone deacetylase inhibitors, and their  
 therapeutic use  
 IN Chakravarty, Prasun K.; Kuo, Howard; Matthews, Jay M.; Meinke, Peter T.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006017214	A2	20060216	WO 2005-US24512	20050708
	WO 2006017214	A3	20060601		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

US 2004-587233P P 20040712

OS MARPAT 144:343645  
 AB The invention discloses hydroxamic acid derivs. that are inhibitors of histone deacetylase. The compds. are useful for treating cellular proliferative diseases, including cancer. Further, the compds. are useful for treating neurodegenerative diseases, schizophrenia, and stroke, among other diseases. The compds. also have antiprotozoal properties. Compound preparation is included.

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors  
 AN 2005:604284 CAPLUS  
 DN 143:259486  
 TI Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors  
 AU Lu, Qiang; Wang, Da-Sheng; Chen, Chang-Shi; Hu, Yuan-Dong; Chen, Ching-Shih  
 CS Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA  
 SO Journal of Medicinal Chemistry (2005), 48(17), 5530-5535  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB Previously, the authors developed a strategy to develop a novel class of histone deacetylase (HDAC) inhibitors by tethering short-chain fatty acids with Zn<sup>2+</sup>-chelating motifs, which led to N-hydroxy-4-(4-phenylbutyryl-amino)benzamide (HTPB), a hydroxamate-tethered phenylbutyrate derivative with sub-micromolar potency in inhibiting HDAC activity and cancer cell proliferation. In this study, the authors carried out structure-based optimization of HTPB by using the framework generated by the structure of histone deacetylase-like protein (HDLF)-trichostatin A (TSA) complexes. Docking of HTPB into the HDLP binding domain suggested that the hydrophobic microenvironment encompassed by Phe-198 and Phe-200 could be

exploited for structural optimization. This premise was corroborated by the greater potency of (S)-(+)-N-hydroxy-4-(3-methyl-2-phenylbutyrylamino)-benzamide [(S)-11] (IC50 in HDAC inhibition, 16 nM), of which the iso-Pr moiety was favorable in interacting with this hydrophobic motif. (S)-11 at concns. as low as 0.1  $\mu$ M was effective in causing histone hyperacetylation and p21WAF/CIP1 overexpression and suppressing proliferation in cancer cells.

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors and their use as anticancer agents  
AN 2005:540452 CAPLUS  
DN 143:55641  
TI Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors and their use as anticancer agents  
IN Chen, Ching-Shih; Qiang, Lu  
PA The Ohio State University Research Foundation, USA  
SO PCT Int. Appl., 90 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005055928	A2	20050623	WO 2004-US40211	20041201
WO 2005055928	A3	20051006		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004296764	A1	20050623	US 2003-526348P	P 20031202
			AU 2004-296764	20041201
			US 2003-526348P	P 20031202
			WO 2004-US40211	W 20041201
CA 2552279	A1	20050623	CA 2004-2552279	20041201
			US 2003-526348P	P 20031202
			WO 2004-US40211	W 20041201
EP 1696898	A2	20060906	EP 2004-812666	20041201
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
			US 2003-526348P	P 20031202
			WO 2004-US40211	W 20041201



OS MARPAT 143:55641

AB The invention relates to histone deacetylase (HDAC) inhibitors including Zn2+-chelating motifs, based on short-chain fatty acids. Preparation of the HDAC inhibitors is described. Some of the HDAC inhibitors displayed antiproliferative activities at sub- $\mu$ M concns. and can be used as anticancer agents. The compds. performed well in in vitro and in vivo tests.

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.  
AN 2005:182616 CAPLUS

DN 142:279954  
 TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.  
 IN Rho, Ho Sik; Baek, Heung Soo; Kim, Su Jong; Kim, Su Nam; Chae, Byung Geun; Lee, Byoung Seok; Kim, Bae Hwan; Choi, Gyu Ho; Son, Eui Dong; Lee, Hae Kwang; Lee, Hye Won; Cho, Jun-cheol; Kim, Duck Hee; Chang, Ih Seop; Lee, Ok Sub  
 PA Amorepacific Corporation, S. Korea  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019162	A1	20050303	WO 2004-KR2143	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
	KR 2006005892	A	20060118	KR 2004-54886	20040714
	EP 1660437	A1	20060531	EP 2004-774404	20040826
	R: FR				
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
	CN 1839115	A	20060927	WO 2004-KR2143	W 20040826
				CN 2004-80024139	20040826
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
	US 2006252834	A1	20061109	WO 2004-KR2143	W 20040826
				US 2006-595124	20060615
				KR 2003-59177	A 20030826
				KR 2004-20401	A 20040325
				KR 2004-54886	A 20040714
				WO 2004-KR2143	W 20040826
OS	MARPAT 142:279954				
GI					



AB Title compds. [I; R1 = adamantyl, Q1; R5, R6 = H, alkyl, cycloalkyl; R2 = CONH, NHCO, CONR7, NR7CO; R7 = alkyl; R3 = (CH)n; n = 0, 1; R4 = H, alkyl], were prepared Thus, 4-(phenylcarbonylamino)benzoic acid (preparation

given) in pyridine at 10° was treated dropwise with Et chloroformate followed by stirring for 2 h at room temperature to give the anhydride. This was added to NH<sub>2</sub>OH.HCl in pyridine at 10° followed by stirring for 30 min. to give 65% N-[4-(N-hydroxycarbamoyl)phenyl]benzamide. The latter reduced collagenase expression in vitro to 78% of controls, vs. 85% for retinol.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors

AN 2003:1000679 CAPLUS

DN 140:246111

TI Structure-activity relationships by mass spectrometry: identification of novel MMP-3 inhibitors

AU Ockey, Denise A.; Dotson, Jenna L.; Struble, Martin E.; Stults, John T.; Bourell, James H.; Clark, Kevin R.; Gadek, Thomas R.

CS Department of Bioorganic Chemistry, Genentech Inc., South San Francisco, CA, 94080, USA

SO Bioorganic & Medicinal Chemistry (2004), 12(1), 37-44  
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 140:246111

AB A novel class of nonpeptide inhibitors of stromelysin (MMP-3) has been discovered with the use of mass spectrometry. The method relies on the development of structure-activity relationships by mass spectrometry (SAR by MS) and utilizes information derived from the binding of known inhibitors to identify novel inhibitors of a target protein with a min. of synthetic effort. Noncovalent complexes of known inhibitors with a target protein are analyzed; these inhibitors are deconstructed into sets of fragments which compete for common or overlapping binding sites on the target protein. The binding of each fragment set can be studied independently. With the use of competition studies, novel members of each fragment set are identified from compound libraries that bind to the same site on the target protein. A novel inhibitor of the target protein was then constructed by chemical linking a combination of members of each fragment set in a manner guided by the proximity and orientation of the fragments derived from the known inhibitors. In the case of stromelysin, a novel inhibitor composed of favorably linked fragments was observed to form a 1:1 complex with stromelysin. Compds. that were not linked appropriately formed higher order complexes with stoichiometries of 2:1 or greater. These linked mols. were subsequently assessed for their ability to block stromelysin function in a chromogenic substrate assay.

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Identification of noncovalent complexes by mass spectrometry, and use in identifying drug leads

AN 2002:889446 CAPLUS

DN 137:363032

TI Identification of noncovalent complexes by mass spectrometry, and use in identifying drug leads

IN Gadek, Thomas R.; Ockey, Denise

PA USA

SO U.S. Pat. Appl. Publ., 29 pp.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002172967	A1	20021121	US 2002-73077 US 2001-268556P	20020212 P 20010213
AB	Methods are disclosed for identifying drug leads or binding compds. that have an affinity for a target mol. involving screening known drug fragment mols. and derivs. thereof, preferably using mass spectrometry.				

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Preparation of arylhydroxamates and related compounds as potent inducers of terminal differentiation.  
 AN 1998:8261 CAPLUS  
 DN 128:75197  
 TI Preparation of arylhydroxamates and related compounds as potent inducers of terminal differentiation.  
 IN Breslow, Ronald; Marks, Paul A.; Rifkind, Richard A.  
 PA Sloan-Kettering Institute for Cancer Research, USA  
 SO U.S., 24 pp., Cont.-in-part of U.S. 5,369,108.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5700811	A	19971223	US 1994-246363	19940519
				US 1991-771760	A2 19911004
	US 5369108	A	19941129	US 1991-771760	19911004
	HU 67421	A2	19950428	HU 1994-959	19921005
				US 1991-771760	A 19911004
	AT 183185	T	19990815	AT 1992-922033	19921005
				US 1991-771760	A 19911004
	ES 2134815	T3	19991016	ES 1992-922033	19921005
				US 1991-771760	A 19911004
	JP 2003226680	A	20030812	JP 2002-337049	19921005
				US 1991-771760	A 19911004
				JP 1993-507109	A3 19921005
	US 5932616	A	19990803	US 1994-222685	19940404
				US 1991-771760	A3 19911004
	CA 2190765	A1	19951130	CA 1995-2190765	19950519
				US 1994-246363	A 19940519
	WO 9531977	A1	19951130	WO 1995-US6554	19950519
	W: AU, CA, JP, MX RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1994-246363	A 19940519
	AU 9526474	A	19951218	AU 1995-26474	19950519
	AU 692561	B2	19980611		
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519
	EP 760657	A1	19970312	EP 1995-921378	19950519
	EP 760657	B1	20031112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519
	AT 253906	T	20031115	AT 1995-921378	19950519
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519
	ES 2210293	T3	20040701	ES 1995-921378	19950519
				US 1994-246363	A 19940519
	AU 9662063	A	19961017	AU 1996-62063	19960813
	AU 708115	B2	19990729		
				US 1991-771760	A 19911004
	US 6087367	A	20000711	US 1999-314195	19990518
				US 1991-771760	A3 19911004

US 38506	E1	20040420	US 1994-222685	A1 19940404
			US 2001-4411	20011102
			US 1991-771760	A5 19911004

PATENT FAMILY INFORMATION:

FAN 1993:538765

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9307148	A1	19930415	WO 1992-US8454	19921005
W: AU, CA, FI, HU, JP, KR, NO, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
US 5369108	A	19941129	US 1991-771760	A 19911004
AU 9228703	A	19930503	US 1991-771760	19911004
AU 668696	B2	19960516	AU 1992-28703	19921005
			US 1991-771760	A 19911004
			WO 1992-US8454	A 19921005
EP 642509	A1	19950315	EP 1992-922033	19921005
EP 642509	B1	19990811		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
			US 1991-771760	A 19911004
			WO 1992-US8454	W 19921005
JP 07502494	T	19950316	JP 1993-507109	19921005
JP 3432823	B2	20030804		
			US 1991-771760	A 19911004
			WO 1992-US8454	W 19921005
HU 67421	A2	19950428	HU 1994-959	19921005
			US 1991-771760	A 19911004
RU 2128643	C1	19990410	RU 1994-21660	19921005
			US 1991-771760	A 19911004
			WO 1992-US8454	W 19921005
AT 183185	T	19990815	AT 1992-922033	19921005
			US 1991-771760	A 19911004
ES 2134815	T3	19991016	ES 1992-922033	19921005
			US 1991-771760	A 19911004
JP 2003226680	A	20030812	JP 2002-337049	19921005
			US 1991-771760	A 19911004
			JP 1993-507109	A3 19921005
CA 2120619	C	20061121	CA 1992-2120619	19921005
			US 1991-771760	A 19911004
			WO 1992-US8454	W 19921005
NO 9401166	A	19940530	NO 1994-1166	19940329
			US 1991-771760	A 19911004
			WO 1992-US8454	A 19921005
FI 9401537	A	19940531	FI 1994-1537	19940331
			US 1991-771760	A 19911004
			WO 1992-US8454	W 19921005
US 5932616	A	19990803	US 1994-222685	19940404
			US 1991-771760	A3 19911004
AU 9662063	A	19961017	AU 1996-62063	19960813
AU 708115	B2	19990729		
			US 1991-771760	A 19911004
US 6087367	A	20000711	US 1999-314195	19990518
			US 1991-771760	A3 19911004
			US 1994-222685	A1 19940404
US 38506	E1	20040420	US 2001-4411	20011102
			US 1991-771760	A5 19911004

FAN 1996:181546

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9531977	A1	19951130	WO 1995-US6554	19950519
W: AU, CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			US 1994-246363	A 19940519

US 5700811	A	19971223	US 1994-246363	19940519
			US 1991-771760	A2 19911004
AU 9526474	A	19951218	AU 1995-26474	19950519
AU 692561	B2	19980611		
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
EP 760657	A1	19970312	EP 1995-921378	19950519
EP 760657	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
AT 253906	T	20031115	AT 1995-921378	19950519
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519

OS MARPAT 128:75197

AB R1CO(CH2)nCOR2 [R1 = R2 = (substituted) arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino; or R1 ≠ R2 and R1 = NR3R4; R3, R4 = H, OH, (substituted) alkyl, alkenyl, cycloalkyl, aryl, alkoxy, aryloxy, aralkoxy, pyridyl; R3R4N = piperidino; n = 4-8; R2 = hydroxylamino, OH, amino, alkoxy], and related compds., were prepared Thus, 3-HONHCOC6H4CH:CHCONHOH (prepared by reaction of H2NOSiMe3 with the corresponding diacid dichloride) induced terminal differentiation with an optimal concentrate of 4 μM with 73% benzidine reactive cells.

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of alkanedicarboxylic acid amides as novel potent inducers of terminal differentiation of neoplastic cell

AN 1996:181546 CAPLUS

DN 124:260602

TI Preparation of alkanedicarboxylic acid amides as novel potent inducers of terminal differentiation of neoplastic cell

IN Breslow, Ronald; Marks, Paul A.; Rifkind, Richard A.

PA Sloan-Kettering Institute for Cancer Research, USA; Trustees of Columbia University in the City of New York

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9531977	A1	19951130	WO 1995-US6554	19950519
	W: AU, CA, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5700811	A	19971223	US 1994-246363	A 19940519
				US 1994-246363	19940519
	AU 9526474	A	19951218	US 1991-771760	A2 19911004
	AU 692561	B2	19980611	AU 1995-26474	19950519
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519
	EP 760657	A1	19970312	EP 1995-921378	19950519
	EP 760657	B1	20031112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519
	AT 253906	T	20031115	AT 1995-921378	19950519
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519

PATENT FAMILY INFORMATION:

FAN 1993:538765

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 9307148	A1	19930415	WO 1992-US8454	19921005
	W: AU, CA, FI, HU, JP, KR, NO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5369108	A	19941129	US 1991-771760	A 19911004
	AU 9228703	A	19930503	US 1991-771760	19911004
	AU 668696	B2	19960516	AU 1992-28703	19921005
				US 1991-771760	A 19911004
	EP 642509	A1	19950315	WO 1992-US8454	A 19921005
	EP 642509	B1	19990811	EP 1992-922033	19921005
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	JP 07502494	T	19950316	JP 1993-507109	19921005
	JP 3432823	B2	20030804		
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	HU 67421	A2	19950428	HU 1994-959	19921005
				US 1991-771760	A 19911004
	RU 2128643	C1	19990410	RU 1994-21660	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	AT 183185	T	19990815	AT 1992-922033	19921005
				US 1991-771760	A 19911004
	ES 2134815	T3	19991016	ES 1992-922033	19921005
				US 1991-771760	A 19911004
	JP 2003226680	A	20030812	JP 2002-337049	19921005
				US 1991-771760	A 19911004
				JP 1993-507109	A3 19921005
	CA 2120619	C	20061121	CA 1992-2120619	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	NO 9401166	A	19940530	NO 1994-1166	19940329
				US 1991-771760	A 19911004
				WO 1992-US8454	A 19921005
	FI 9401537	A	19940531	FI 1994-1537	19940331
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	US 5932616	A	19990803	US 1994-222685	19940404
				US 1991-771760	A3 19911004
	AU 9662063	A	19961017	AU 1996-62063	19960813
	AU 708115	B2	19990729		
				US 1991-771760	A 19911004
	US 6087367	A	20000711	US 1999-314195	19990518
				US 1991-771760	A3 19911004
				US 1994-222685	A1 19940404
	US 38506	E1	20040420	US 2001-4411	20011102
				US 1991-771760	A5 19911004

FAN	1998:8261				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5700811	A	19971223	US 1994-246363	19940519
				US 1991-771760	A2 19911004
	US 5369108	A	19941129	US 1991-771760	19911004
	HU 67421	A2	19950428	HU 1994-959	19921005
				US 1991-771760	A 19911004
	AT 183185	T	19990815	AT 1992-922033	19921005
				US 1991-771760	A 19911004
	ES 2134815	T3	19991016	ES 1992-922033	19921005
				US 1991-771760	A 19911004
	JP 2003226680	A	20030812	JP 2002-337049	19921005
				US 1991-771760	A 19911004

US 5932616	A	19990803	JP 1993-507109	A3 19921005
			US 1994-222685	19940404
CA 2190765	A1	19951130	US 1991-771760	A3 19911004
			CA 1995-2190765	19950519
WO 9531977	A1	19951130	US 1994-246363	A 19940519
W: AU, CA, JP, MX			WO 1995-US6554	19950519
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			US 1994-246363	A 19940519
AU 9526474	A	19951218	AU 1995-26474	19950519
AU 692561	B2	19980611		
			US 1994-246363	A 19940519
EP 760657	A1	19970312	WO 1995-US6554	W 19950519
EP 760657	B1	20031112	EP 1995-921378	19950519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
AT 253906	T	20031115	AT 1995-921378	19950519
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
ES 2210293	T3	20040701	ES 1995-921378	19950519
			US 1994-246363	A 19940519
AU 9662063	A	19961017	AU 1996-62063	19960813
AU 708115	B2	19990729		
			US 1991-771760	A 19911004
US 6087367	A	20000711	US 1999-314195	19990518
			US 1991-771760	A3 19911004
			US 1994-222685	A1 19940404
US 38506	E1	20040420	US 2001-4411	20011102
			US 1991-771760	A5 19911004
OS	MARPAT 124:260602			
AB	<p>Alkanedicarboxylic acid amides <math>R_1CO(CH_2)_nCOR_2</math> [I; wherein each of <math>R_1</math> and <math>R_2</math> are independently the same or different from each other; <math>R_1</math> and <math>R_2</math> are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; when <math>R_1</math> and <math>R_2</math> are different, <math>R_1 = R_3-NR_4</math>, wherein each of <math>R_3</math> and <math>R_4</math> are independently the same as or different from each other and are H, HO, (un)substituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or <math>R_3</math> and <math>R_4</math> bond together to form a piperidine group and <math>R_2</math> is a hydroxylamino, HO, <math>NH_2</math>, alkylamino, dialkylamino or alkyloxy group; <math>n =</math> an integer from about 4-8], which inhibit proliferation of such cells and are useful for treating a patient having a tumor characterized by proliferation of neoplastic cells, are prepared Thus, chlorination of suberic acid monomethyl ester with oxalyl chloride benzene containing DMF to suberoyl chloride followed by condensation with O-benzylhydroxylamine in pyridine/<math>CHCl_3</math> at room temperature overnight gave 89% <math>PhCH_2ONHCO(CH_2)_6CO_2Me</math>. Hydrogenolysis of the latter compound in the presence of 5% Pd-C under .apprx.50 psi H atmospheric to <math>HONHC(O)(CH_2)_6CO_2Me</math> followed by saponification with KOH in aqueous MeOH under reflux for 2 h and acidification with concentrated HCl gave <math>HONHC(O)(CH_2)_6CO_2H</math>. <math>PhONHC(O)(CH_2)_6C(O)NHOH</math> at 3 <math>\mu M</math> in vitro induced the differentiation of MELC cells and HL-60 human leukemia cells by 21 and 65%, resp.</p>			
L5	ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN			
TI	Alkanedioic acid derivatives, novel potent inducers of terminal differentiation and methods of use thereof			
AN	1993:538765 CAPLUS			
DN	119:138765			
TI	Alkanedioic acid derivatives, novel potent inducers of terminal differentiation and methods of use thereof			

IN Breslow, Ronald; Marks, Paul A.; Rifkind, Richard A.; Jursic, Branko  
 PA Sloan-Kettering Institute for Cancer Research; USA; Columbia University  
 SO PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307148	A1	19930415	WO 1992-US8454	19921005
	W: AU, CA, FI, HU, JP, KR, NO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5369108	A	19941129	US 1991-771760	A 19911004
	AU 9228703	A	19930503	US 1991-771760	19911004
	AU 668696	B2	19960516	AU 1992-28703	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	A 19921005
	EP 642509	A1	19950315	EP 1992-922033	19921005
	EP 642509	B1	19990811		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	JP 07502494	T	19950316	JP 1993-507109	19921005
	JP 3432823	B2	20030804		
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	HU 67421	A2	19950428	HU 1994-959	19921005
				US 1991-771760	A 19911004
	RU 2128643	C1	19990410	RU 1994-21660	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	AT 183185	T	19990815	AT 1992-922033	19921005
				US 1991-771760	A 19911004
	ES 2134815	T3	19991016	ES 1992-922033	19921005
				US 1991-771760	A 19911004
	JP 2003226680	A	20030812	JP 2002-337049	19921005
				US 1991-771760	A 19911004
				JP 1993-507109	A3 19921005
	CA 2120619	C	20061121	CA 1992-2120619	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	NO 9401166	A	19940530	NO 1994-1166	19940329
				US 1991-771760	A 19911004
				WO 1992-US8454	A 19921005
	FI 9401537	A	19940531	FI 1994-1537	19940331
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	US 5932616	A	19990803	US 1994-222685	19940404
				US 1991-771760	A3 19911004
	AU 9662063	A	19961017	AU 1996-62063	19960813
	AU 708115	B2	19990729		
				US 1991-771760	A 19911004
	US 6087367	A	20000711	US 1999-314195	19990518
				US 1991-771760	A3 19911004
				US 1994-222685	A1 19940404
	US 38506	E1	20040420	US 2001-4411	20011102
				US 1991-771760	A5 19911004

PATENT FAMILY INFORMATION:

FAN 1996:181546

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9531977	A1	19951130	WO 1995-US6554	19950519

		W: AU, CA, JP, MX			
		RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
US 5700811	A	19971223	US 1994-246363	A	19940519
			US 1994-246363		19940519
AU 9526474	A	19951218	US 1991-771760	A2	19911004
AU 692561	B2	19980611	AU 1995-26474		19950519
			US 1994-246363	A	19940519
EP 760657	A1	19970312	WO 1995-US6554	W	19950519
EP 760657	B1	20031112	EP 1995-921378		19950519
		R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
AT 253906	T	20031115	AT 1995-921378		19950519
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
FAN 1998:8261					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
-----	-----	-----	-----		-----
PI US 5700811	A	19971223	US 1994-246363		19940519
			US 1991-771760	A2	19911004
US 5369108	A	19941129	US 1991-771760		19911004
HU 67421	A2	19950428	HU 1994-959		19921005
			US 1991-771760	A	19911004
AT 183185	T	19990815	AT 1992-922033		19921005
			US 1991-771760	A	19911004
ES 2134815	T3	19991016	ES 1992-922033		19921005
			US 1991-771760	A	19911004
JP 2003226680	A	20030812	JP 2002-337049		19921005
			US 1991-771760	A	19911004
			JP 1993-507109	A3	19921005
US 5932616	A	19990803	US 1994-222685		19940404
			US 1991-771760	A3	19911004
CA 2190765	A1	19951130	CA 1995-2190765		19950519
			US 1994-246363	A	19940519
WO 9531977	A1	19951130	WO 1995-US6554		19950519
		W: AU, CA, JP, MX			
		RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
			US 1994-246363	A	19940519
AU 9526474	A	19951218	AU 1995-26474		19950519
AU 692561	B2	19980611			
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
EP 760657	A1	19970312	EP 1995-921378		19950519
EP 760657	B1	20031112			
		R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
AT 253906	T	20031115	AT 1995-921378		19950519
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
ES 2210293	T3	20040701	ES 1995-921378		19950519
			US 1994-246363	A	19940519
AU 9662063	A	19961017	AU 1996-62063		19960813
AU 708115	B2	19990729			
			US 1991-771760	A	19911004
US 6087367	A	20000711	US 1999-314195		19990518
			US 1991-771760	A3	19911004
			US 1994-222685	A1	19940404
US 38506	E1	20040420	US 2001-4411		20011102
			US 1991-771760	A5	19911004
OS MARPAT 119:138765					

AB Alkylene bisamides and monoamides  $R_1CO(CH_2)_nCOR_2$  [ $R_1 = R_2 =$  (un)substituted arylamino, cycloalkylamino, pyridylamino, piperidino, 9-purine-6-amino, thiazolylamino;  $R_1 = R_3R_4N$ , where  $R_3 = H, OH$ , (un)substituted alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, pyridyl or  $R_3R_4N =$  piperidino;  $R_2 =$  hydroxyamino, hydroxy, amino, alkylamino, dialkylamino, alkyloxy;  $n = 4-8$ ] were prepared for selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting their proliferation (data tabulated). Thus, a pyridine solution of  $H_2NOCH_2Ph$ ,  $H_2NOMe$ , and suberoyl chloride was stirred overnight at room temperature. The product was treated with 10% HCl in  $HCCl_3-MeOH$  and hydrogenated over 5% Pd/C to give  $HONHCO(CH_2)_6CONHOMe$ .

=> 19/thu

L9 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.33	225.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.75	-7.50

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 08:07:28 ON 27 DEC 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 08:29:29 ON 27 DEC 2006  
FILE 'CAPLUS' ENTERED AT 08:29:29 ON 27 DEC 2006  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.33	225.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.75	-7.50

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.33	225.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.75	-7.50



FILE 'REGISTRY' ENTERED AT 08:29:41 ON 27 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6  
DICTIONARY FILE UPDATES: 26 DEC 2006 HIGHEST RN 916310-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>


=> e 1,4-Benzenedicarboxamide, N-(4-ethylphenyl)-N'-hydroxy-/cn  
MISMATCHED QUOTE IN EXPAND TERM  
Quotation marks (or apostrophes) must be used in pairs,  
one before and one after the expression you are setting  
off or masking.

=> e 1,4-Benzenedicarboxamide, N-(4-ethylphenyl)-N-hydroxy-/cn  
E1 1 1,4-BENZENEDICARBOXAMIDE, N-(4-ETHYLPHENYL)-N'-HYDROXY-/CN  
E2 1 1,4-BENZENEDICARBOXAMIDE, N-(4-ETHYLPHENYL)-N'-HYDROXY-N-MET  
HYL-/CN  
E3 0 --> 1,4-BENZENEDICARBOXAMIDE, N-(4-ETHYLPHENYL)-N-HYDROXY-/CN  
E4 1 1,4-BENZENEDICARBOXAMIDE, N-(4-METHYL-3-((5-(3-PYRIDINYL)-2-  
OXAZOLYL)AMINO)PHENYL)-/CN  
E5 1 1,4-BENZENEDICARBOXAMIDE, N-(4-METHYL-5-(((1S,2S)-2-(PHENYL  
METHOXY)CYCLOPENTYL)AMINO)CARBONYL)-2-THIAZOLYL)-/CN  
E6 1 1,4-BENZENEDICARBOXAMIDE, N-(49-((3AS,4S,6AR)-HEXAHYDRO-2-  
OXO-1H-THIENO(3,4-D)IMIDAZOL-4-YL)-31,38,45-TRIOXO-3,6,9,12,15  
,18,21,24,27-NONAOXA-30,37,44-TRIAZANONATETRACONT-1-YL)-N'-(  
4-METHYL-3-((4-(3-PY/CN  
E7 2 1,4-BENZENEDICARBOXAMIDE, N-(5-(((3,5-BIS(1,1-DIMETHYLETHYL)  
-4-HYDROXYPHENYL)ACETYL)AMINO)-1-((OCTAHYDRO-2-(((3,3,3-TRIF  
LUORO-1-(1-METHYLETHYL)-2-OXOPROPYL)AMINO)CARBONYL)-1H-INDOL  
-1-YL)CARBONYL)PENTYL)/CN  
E8 1 1,4-BENZENEDICARBOXAMIDE, N-(5-(((5-(((2-CYANOETHYL)AMINO)CA  
RBONYL)-1-METHYL-1H-PYRROL-3-YL)AMINO)CARBONYL)-1-METHYL-1H-  
PYRROL-3-YL)-N'-(4-(((4-((3-CYANO-1-OXOPROPYL)AMINO)-1-METHY  
L-1H-PYRROL-2-YL)CAR/CN  
E9 2 1,4-BENZENEDICARBOXAMIDE, N-(5-(((4-((3,5-BIS(1,1-DIMETHYLETH  
YL)-4-HYDROXYPHENYL)THIO)-1-OXOBUTYL)AMINO)-1-((OCTAHYDRO-2-  
(((3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPROPYL)AMINO)CARBO  
NYL)-1H-INDOL-1-YL)C/CN  
E10 1 1,4-BENZENEDICARBOXAMIDE, N-(5-(2,2-DIMETHYL-1-OXOPROPYL)-1,  
4,5,6-TETRAHYDRO-6,6-DIMETHYLPYRROLO(3,4-C)PYRAZOL-3-YL)-/CN  
E11 1 1,4-BENZENEDICARBOXAMIDE, N-(5-(3,5-DICHLORO-2-HYDROXYPHENYL  
)-1,3,4-THIADIAZOL-2-YL)-N'-(2,5-DIFLUOROPHENYL)-/CN  
E12 1 1,4-BENZENEDICARBOXAMIDE, N-(5-(3,5-DICHLORO-2-HYDROXYPHENYL  
)-1,3,4-THIADIAZOL-2-YL)-N'-(2-METHOXY-5-NITROPHENYL)-/CN

=> e1  
L6 1 "1,4-BENZENEDICARBOXAMIDE, N-(4-ETHYLPHENYL)-N'-HYDROXY-"/CN

=> d 16

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 847250-13-9 REGISTRY  
ED Entered STN: 25 Mar 2005  
CN 1,4-Benzenedicarboxamide, N-(4-ethylphenyl)-N'-hydroxy- (9CI)  
(CA INDEX NAME)  
MF C16 H16 N2 O3  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.54	232.86

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-7.50

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 08:30:42 ON 27 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Dec 2006 VOL 146 ISS 1  
FILE LAST UPDATED: 26 Dec 2006 (20061226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 16

L7 1 L6

=> d 17

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:182616 CAPLUS  
DN 142:279954  
TI Preparation of arylhydroxamates as elastase and collagenase expression  
inhibitors for preventing skin aging.  
IN Rho, Ho Sik; Baek, Heung Soo; Kim, Su Jong; Kim, Su Nam; Chae, Byung Geun;  
Lee, Byoung Seok; Kim, Bae Hwan; Choi, Gyu Ho; Son, Eui Dong; Lee, Hae  
Kwang; Lee, Hye Won; Cho, Jun-cheol; Kim, Duck Hee; Chang, Ih Seop; Lee,  
Ok Sub  
PA Amorepacific Corporation, S. Korea  
SO PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019162	A1	20050303	WO 2004-KR2143	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	KR 2006005892	A	20060118	KR 2004-54886	20040714
	EP 1660437	A1	20060531	EP 2004-774404	20040826
	R: FR				
	CN 1839115	A	20060927	CN 2004-80024139	20040826
	US 2006252834	A1	20061109	US 2006-595124	20060615
PRAI	KR 2003-59177	A	20030826		
	KR 2004-20401	A	20040325		
	KR 2004-54886	A	20040714		
	WO 2004-KR2143	W	20040826		

OS MARPAT 142:279954

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.06	234.92

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-7.50

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 08:31:45 ON 27 DEC 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 09:52:52 ON 27 DEC 2006  
FILE 'CAPLUS' ENTERED AT 09:52:52 ON 27 DEC 2006  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.06	234.92
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.50

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.52	235.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.50

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 09:53:10 ON 27 DEC 2006